Evidence map›Paper›PMID 42846871›Full record

ReviewJournal of arrhythmia2026

Clinical Advantages and Pitfalls of Pulsed Field Ablation: How to Prevent ALH Syndrome.

Hiroshi Nakagawa, Quim Castellvi, Masafumi Sugawara, Atsushi Ikeda, Salman Farshchi-Heydari, Jennifer Maffre, Ayman A Hussein, Pasquale Santangeli, Walid I Saliba, Yukihito Higashi and 1 more

Abstract readReview
In one paragraph

Review in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hiroshi NakagawaDepartment of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA.ORCID https://orcid.org/0000-0001-9368-519X
Quim CastellviDepartment of Engineering Universitat Pompeu Fabra Barcelona Spain.ORCID https://orcid.org/0000-0002-7095-1181
Masafumi SugawaraDepartment of Cardiology Chiba University Chiba Japan.ORCID https://orcid.org/0009-0002-8142-8000
Atsushi IkedaDepartment of Cardiology Akiru Municipal Medical Center Tokyo Japan.ORCID https://orcid.org/0009-0006-7043-7795
Salman Farshchi-HeydariJohnson & Johnson MedTech Irvine California USA.ORCID https://orcid.org/0009-0003-5158-1482
Jennifer MaffreJohnson & Johnson MedTech Irvine California USA.
Ayman A HusseinDepartment of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA.ORCID https://orcid.org/0000-0002-8359-1525
Pasquale SantangeliDepartment of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA.ORCID https://orcid.org/0000-0002-0023-9666
Walid I SalibaDepartment of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio USA.ORCID https://orcid.org/0000-0003-3324-8611
Yukihito HigashiDepartment of Regenerative Medicine, Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan.ORCID https://orcid.org/0000-0001-5813-3672
Warren M JackmanHeart Rhythm Institute University of Oklahoma Oklahoma City Oklahoma USA.ORCID https://orcid.org/0000-0002-0023-7054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catheter ablation for tachyarrhythmias was first introduced in the early 1980s using direct-current (DC) energy. Following the clinical introduction of radiofrequency (RF) ablation in the late 1980s, thermal ablation technologies became the foundation of catheter ablation because of their superior controllability, efficacy, and safety. In 2014, Wittkampf developed a DC-energy-delivery catheter system preventing electrical arcing, thereby initiating a modern "revival of DC-ablation" based on catheter ablation using electroporation. Subsequent development of high-voltage, short-duration pulse-train delivery led to the emergence of pulsed field ablation (PFA). Exposure of myocytes to high-voltage electric fields induces reversible electroporation through nanoscale pore formation within the lipid bilayer, whereas higher electric-field delivery produces irreversible electroporation, resulting in permanent membrane disruption, apoptosis, and durable lesion formation. PFA is regarded as a predominantly nonthermal and potentially tissue-selective ablation modality. Nevertheless, clinical trials of pulmonary vein isolation for atrial fibrillation have demonstrated that PFA is noninferior to conventional thermal ablation strategies, although clear superiority-other than shorter procedural times-has not yet been established. Importantly, recent studies suggest that electrode-tissue contact remains a critical determinant of durable lesion formation. Accumulating evidence indicates that PFA is associated with new complications not commonly observed with thermal ablation, including acute kidney injury, stroke, coronary vasospasm, myocardial ischemia, ventricular fibrillation, and sudden cardiac death. Although the mechanisms remain incompletely understood, hemolysis-related injury induced by high-voltage pulse delivery may represent an important contributing mechanism. Development of PFA systems capable of real-time prediction of irreversible lesion size may be essential for optimizing both procedural efficacy and safety.

Indexed as

catheter ablationelectrophysiology mappingtachyarrhythmias

Identifiers

PMID42846871
PMCPMC13643947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.